BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management

Reuters2024-11-29

Nov 29 (Reuters) - Silo Pharma Inc SILO.O:

SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT FOR SP-26 KETAMINE IMPLANT DEVICE TARGETING PAIN MANAGEMENT
SILO PHARMA INC - KYMANOX TO CONDUCT PROOF-OF-CONCEPT AND FEASIBILITY TESTING FOR SP-26

Source text: ID:nGNX8WQtH0

Further company coverage: SILO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487001559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487001559","market":"us","top_or_hot":-1,"title":"BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management</title></head><body><p><span>Nov 29 (Reuters)</span><span> - </span>Silo Pharma Inc <span>SILO.O</span>:</p><ul><li><p>SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT FOR SP-26 KETAMINE IMPLANT DEVICE TARGETING PAIN MANAGEMENT</p></li><li><p>SILO PHARMA INC - KYMANOX TO CONDUCT PROOF-OF-CONCEPT AND FEASIBILITY TESTING FOR SP-26</p></li></ul><p>Source text: <span>ID:nGNX8WQtH0</span></p><p>Further company coverage: <span>SILO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain Management\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA8T3N9G:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain ManagementNov 29 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA8T3N9G:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4202","symbol_name":"服装、服饰与奢侈品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUA8T3N9G:1","article_id":"2487001559","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487001559","pubTimestamp":1732885997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain ManagementNov 29 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4202":"服装、服饰与奢侈品","BK4139":"生物科技","SILO":"SILO PHARMA INC."},"translate_title":"简介-Silo Pharma签署针对疼痛管理的Sp-26氯胺酮植入装置联合开发协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SILO":0.9},"content_text":"BRIEF-Silo Pharma Enters Joint Development Agreement For Sp-26 Ketamine Implant Device Targeting Pain ManagementNov 29 (Reuters) - Silo Pharma Inc SILO.O:SILO PHARMA ENTERS JOINT DEVELOPMENT AGREEMENT FOR SP-26 KETAMINE IMPLANT DEVICE TARGETING PAIN MANAGEMENTSILO PHARMA INC - KYMANOX TO CONDUCT PROOF-OF-CONCEPT AND FEASIBILITY TESTING FOR SP-26Source text: ID:nGNX8WQtH0Further company coverage: SILO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487001559"}